SOLICITATION NOTICE
66 -- U-PLEX Custom Biomarker Plates
- Notice Date
- 12/13/2016
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HL)-2017-051-KMA
- Archive Date
- 1/3/2017
- Point of Contact
- Kevin Alvarez,
- E-Mail Address
-
kevin.alvarez@nih.gov
(kevin.alvarez@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION. The National Heart, Lung, and Blood Institute (NHLBI), Office of Acquisitions (OA), intends to negotiate and award a purchase order on a noncompetitive sole source basis to Meso Scale Diagnostics, LLC, 1601 Research Blvd, Rockville, MD, 20850-3126, to procure sixty-five (65) additional U-PLEX custom biomarker plates that are required by the lab for processing of patient cell samples. BACKGROUND The Section of Inflammation and Cardiometabolic Diseases' research program focuses on the role of innate immunity and inflammation in the development of cardiovascular and metabolic diseases. The Section has utilized the chronic inflammation state observed in psoriasis, an inflammatory disease that visibly manifests as skin rashes to study the development of cardiometabolic diseases. Through a combination of laboratory, imaging, and clinical studies, the lab has helped to shift the prevailing model of psoriasis, from thinking of it as just a skin disease to a disease of the whole body. This work has shown that people with psoriasis without CVD risk factors are at increased risk of CVD and future vascular events. To further understand the link between inflammation, atherosclerosis, and metabolic diseases, the lab has begun to utilize the NIH Clinical Center to begin a comprehensive cardiometabolic phenotyping program. They see patients with inflammatory diseases at the NIHCC for cardiovascular and metabolic risk assessment, and during that assessment obtain several tissues to characterize inflammatory states. These studies combined with high level multi-modal imaging by FDG PET/CT, FDG PET/MRI and coronary CT angiography will permit the lab to simultaneously measure pathways involved in atherosclerosis and metabolism to better understand how inflammation is associated with heart disease and diabetes. Combined with imaging technology, this study will better inform patients and biology of how inflammation may lead to the development of cardiometabolic diseases. The long term goals of the lab are to improve both risk stratification and risk prediction for CVD in people with inflammatory conditions. They will continue to apply the diverse set of scientific approaches from this mechanistic translational science program to move discoveries from the bench to bedside, and understanding from the bedside back to the bench. PURPOSE The purpose of this acquisition is to procure sixty-five (65) additional U-PLEX custom biomarker plates that are required by the lab for processing of patient cell samples. Over the past two years the lab has confirmed the upregulation of specific biomarkers in the serum, adipose and skin of their psoriasis cohort at both baseline and week-12 visits. These analyses were all performed on custom biomarker plates run on a MSD Sector machine, and additional plates are now needed to process patient samples from the week-52 visits. PROCUREMENT The contractor shall provide the following: •U-PLEX Biomarker Group 1 (hu) Assays, SECTOR (25 PL) oU-PLEX Human GM-CSF oU-PLEX Human IFN-γ oU-PLEX Human IL-1β oU-PLEX Human IL-6 oU-PLEX Human IL-8 oU-PLEX Human IL-17A oU-PLEX Human IL-17F oU-PLEX Human IL-18 oU-PLEX Human MCP-1 oU-PLEX Human TNF-α •Human Leptin, Insulin Kit (20 Plate) •Human Adiponectin Kit (20 Plate) JUSTIFICATION Experimental conditions require that these custom plates sold by Meso Scale Diagnostics continue to be used, as the lab must have consistency throughout this protocol. Consistency is critical to data validity, and they must ensure that experimental protocols are maintained and unchanged for all studies performed. It is imperative for scientific continuity that these plates are consistent with previously utilized plates, as any changes to the protocol (including reagents, instruments, testing conditions, etc.) would invalidate current work practices. REGULATORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source (for purchases not exceeding the simplified acquisition threshold) and only one responsible source and no other supplies or services will satisfy agency requirements. ADDITIONAL INFORMATION Industry Classification (NAICS) Code is 334516, Analytical Laboratory Instrument Manufacturing, and the Small Business Size Standard is 1000 employees. The acquisition is being conducted under FAR Part 13, Simplified Acquisition Procedures, therefore the requirements of FAR Part 6, Competitive Requirements, are not applicable (FAR Part 6.001). The resultant award will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-92 (November 18, 2016). This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by December 19, 2016 at 9:00AM EST and must reference synopsis number NHLBI-CSB-(HL)-2017-051-KMA. Responses shall be submitted to the National Heart, Lung, and Blood Institute, Office of Acquisitions, COAC Services Branch, 6701 Rockledge Drive, Room 6127, Bethesda, Maryland 20892-7902, Attention: Kevin Alvarez. Responses may be submitted electronically to kevin.alvarez@nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HL)-2017-051-KMA/listing.html)
- Record
- SN04349634-W 20161215/161213234003-8e92e2223f4f640105811dbc85d8cc8f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |